Arena BioWorks launches in Cambridge to speed drug discovery

DavidL.Ryan/BostonGlobeAteamofhigh-poweredscientistsandbillionaireinvestorssaidFridaythatthey’relaun ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri




fashion

author：hotspot    Page View：7546
Adobe

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

advertisement

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Ascension's ugly legal battle over care for poor patients in Texas
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts